NEW YORK, NY / ACCESSWIRE / December 14, 2015 / MomentumStockAlert.com is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big potential. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments. Receive our free trade alerts via text message (SMS) and/or email at http://www.MomentumStockAlert.com. Today we are focusing on four companies to watch that have been attracting the attention of major investors.
Anavex Life Sciences Corp. (NASDAQ: AVXL) Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer's disease, central nervous system diseases, and pain and various cancers. AVXL has been making good progress with its lead Alzheimer's drug therapy, ANAVEX 3-71. Late November the company said that ANAVEX 3-71 has tested to be a potent cognitive enhancer in Alzheimer's disease models and that the pre-clinical results will be published in the scientific journal "Neurodegenerative Disease." Shares are trading up this morning off heavy volume.
Sign Up to Receive Hot Small Cap NASDAQ Alerts With Strong Upside Potential. Get Your Free Membership Now.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Akebia Therapeutics is trading higher this morning following news of what looks like a big commercialization partnership in Asia. Shares are already trading up 16% off unusually high volume.
Like What You See? Get These Alerts and Many More on NASDAQ Companies before They Rally, Find Out More Here.
NephroGenex, Inc. (NASDAQ: NRX) NephroGenex, Inc., a drug development company, focuses on developing novel therapies for kidney disease. It develops Pyridorin (pyridoxamine dihydrochoride), a therapeutic agent, which is in Phase III clinical study for the treatment of diabetic nephropathy. NephroGenex announced today that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application for clinical studies with intravenous Pyridorin(R) for the treatment of acute kidney injury. Shares of NephroGenex are trading up over 75% and are trading about 15 times above its average volume.
Get the Information You Need To Stay Informed and Up To Date On The Hottest NASDAQ Plays Get Them Here.
Alon Blue Square Israel Ltd (BSI) Alon Blue Square Israel Ltd. operates as a retail company in Israel. Its Fueling and Commercial Sites segment develops, constructs, and operates vehicle fueling stations, adjacent commercial centers, and independent convenience stores. Alon Blue Square Israel Ltd. (BSI) (the "Company") announced a change in the number of its ordinary shares represented by American Depositary Shares, issued from one ordinary share per ADS to 10 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-10 reverse stock split of the ADSs, reducing the number of outstanding ADSs, as of close of business on December 1, 2015, from 1,228,635 to approximately 122,863 ADSs.